Updating results

151 results

Sort: Relevance | Date

Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)

Summary of the evidence on adjuvant bisphosphonates for preventing recurrence or improving survival in people with early breast cancer

Evidence summary Published July 2017

Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

Summary of the evidence on bezlotoxumab for preventing the recurrence of Clostridium difficile (C difficile) infection

Evidence summary Published June 2017

Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

Summary of the evidence on liraglutide for managing obesity and overweight with risk factors in adults to inform local NHS planning and decision-making

Evidence summary Published June 2017

Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

Summary of the evidence on fluticasone furoate, umeclidinium and vilanterol (Trelegy) for chronic obstructive pulmonary disease (COPD) to inform local NHS

Evidence summary Published June 2018

Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

Summary of the evidence on glycopyrronium bromide for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published January 2013

Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)

Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..

Evidence summary Published July 2013 Last updated September 2014

Transient ischaemic attack: clopidogrel (ESUOM23)

Summary of the evidence on clopidogrel for treating transient ischaemic attack (TIA) to inform local NHS planning and decision-making

Evidence summary Published December 2013

Coronary revascularisation: Cangrelor (ESNM63)

Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making

Evidence summary Published November 2015

Hypersalivation: oral glycopyrronium bromide (ESUOM15)

Summary of the evidence on oral glycopyrronium bromide for treating hypersalivation (sialorrhoea) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Generalised anxiety disorder: quetiapine (ESUOM12)

Summary of the evidence on quetiapine monotherapy for treating generalised anxiety disorder (GAD) to inform local NHS planning and decision-making

Evidence summary Published May 2013

Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

Summary of the evidence on colistimethate sodium (Colobreathe) for non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published January 2014

Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

Evidence summary Published September 2013

Postural hypotension in adults: fludrocortisone (ESUOM20)

Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making

Evidence summary Published October 2013

Significant haemorrhage following trauma: tranexamic acid (ESUOM1)

Summary of the evidence on tranexamic acid for significant haemorrhage (bleeding) after trauma (major injury) to inform local NHS planning and decision-making

Evidence summary Published October 2012

Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)

Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

Evidence summary Published October 2013

Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2)

Summary of the evidence on melatonin for sleep disorders in children and young people with attention deficit hyperactivity disorder (ADHD)..

Evidence summary Published January 2013

Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published January 2013

Symptoms of peripheral arterial disease: ramipril (ESUOM45)

Summary of the evidence on ramipril for relieving the symptoms of peripheral arterial disease (PAD) to inform local NHS planning and decision-making

Evidence summary Published June 2015

Chronic urticaria: off-label doses of cetirizine (ESUOM31)

Summary of the evidence on off-label doses of cetirizine for chronic urticaria (hives) to inform local NHS planning and decision-making

Evidence summary Published July 2014

Scleroderma: oral mycophenolate (ESUOM32)

Summary of the evidence on oral mycophenolate for systemic sclerosis (scleroderma) to inform local NHS planning and decision-making

Evidence summary Published July 2014

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

Evidence summary Published January 2013

Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

Summary of the evidence on carbamazepine for managing aggression, agitation and behavioural disturbances in people with dementia..

Evidence summary Published March 2015

C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

Evidence summary Published December 2015

Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)

Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published March 2013

Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

Summary of the evidence on long-term azithromycin for treating non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published November 2014

Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

Evidence summary Published June 2015

Systemic lupus erythematosus: oral mycophenolate (ESUOM36)

Summary of the evidence on oral mycophenolate for systemic lupus erythematosus (SLE) to inform local NHS planning and decision-making

Evidence summary Published November 2014

Digital ulcers: sildenafil (ESUOM42)

Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making

Evidence summary Published March 2015

Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

Evidence summary Published October 2014

Pulmonary hypertension in neonates: sildenafil (ESUOM51)

Summary of the evidence on sildenafil for treating pulmonary hypertension in neonates to inform local NHS planning and decision-making

Evidence summary Published March 2016

Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)

Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis...

Evidence summary Published October 2014

Fatigue in multiple sclerosis: modafinil (ESUOM9)

Summary of the evidence on modafinil for treating fatigue in multiple sclerosis (MS) to inform local NHS planning and decision-making

Evidence summary Published April 2013

Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)

Summary of the evidence on umeclidinium/vilanterol combination inhaler (Anoro Ellipta) for treating chronic obstructive pulmonary disease (COPD)...

Evidence summary Published November 2014

Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)

Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making

Evidence summary Published October 2015

Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)

Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published December 2015

Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70)

Summary of the evidence on guanfacine prolonged-release for attention deficit hyperactivity disorder (ADHD) to inform local NHS planning and decision-making

Evidence summary Published March 2016

Glaucoma: brinzolamide/brimonidine combination eye drops (ESNM56)

Summary of the evidence on brinzolamide/brimonidine combination eye drops for treating glaucoma to inform local NHS planning and decision-making

Evidence summary Published March 2015

Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)

Summary of the evidence on aclidinium/formoterol for chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published April 2015

Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone) (ESUOM11)

Summary of the evidence on vaginal misoprostol (after oral mifepristone) for induction labour in late intrauterine fetal death (IUFD)..

Evidence summary Published April 2013

Chronic obstructive pulmonary disease: olodaterol (ESNM54)

Summary of the evidence on olodaterol for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published February 2015

Chronic obstructive pulmonary disease: aclidinium bromide (ESNM8)

Summary of the evidence on aclidinium bromide for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published January 2013

Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)

Summary of the evidence on beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) for treating asthma in adults..

Evidence summary Published January 2015

Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)

Summary of the evidence on sucroferric oxyhydroxide for treating hyperphosphataemia in adults with chronic kidney disease (CKD) on dialysis..

Evidence summary Published January 2015

Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)

Summary of the evidence on umeclidinium inhaler (Incruse) for chronic obstructive pulmonary disease to inform local NHS planning and decision-making

Evidence summary Published January 2015

Schizophrenia: lurasidone (ESNM48)

Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

Evidence summary Published September 2014

Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

Evidence summary Published February 2017

Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making

Evidence summary Published March 2017

Premature ejaculation: dapoxetine (ESNM40)

Summary of the evidence on dapoxetine for premature ejaculation to inform local NHS planning and decision-making

Evidence summary Published May 2014

Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)

Summary of the evidence on the levonorgestrel intrauterine delivery system (long-acting reversible contraception) to inform local NHS planning...

Evidence summary Published June 2014

Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)

Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making

Evidence summary Published December 2015